Physician profile
Ryan A Moore
NPI 1386664654
$4,891.65
in general payments reported to CMS, 2019-2025
35 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $135 · 2022: $1,610 · 2023: $1,260 · 2024: $672 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,389 · Education: $35.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,388.90 |
| Education | $35.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,088.98 | 2019-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $417.88 | 2019-2025 | Farxiga |
| Abbvie INC. | $367.29 | 2022-2024 | |
| Lilly USA, LLC | $286.92 | 2019-2025 | Mounjaro, Emgality, Reyvow |
| Pfizer INC. | $218.78 | 2019-2025 | |
| Novo Nordisk INC | $203.99 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Boston Scientific Corporation | $187.13 | 2019-2025 | Lumenis Pulse 120h, General - Pain Management |
| Janssen Pharmaceuticals, INC | $116.68 | 2019-2025 | Spravato |
| Novartis Pharmaceuticals Corporation | $79.71 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $73.29 | 2022-2023 | |
| Rhythm Pharmaceuticals, INC. | $73.29 | 2022-2023 | Imcivree |
| Dexcom, INC. | $70.47 | 2023-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $60.08 | 2019-2025 | Ajovy |
| Merck Sharp & Dohme LLC | $59.21 | 2019-2022 | |
| Glaxosmithkline, LLC. | $51.50 | 2022-2023 | Arexvy, Trelegy Ellipta, Shingrix |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $46.52 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.72 | 2019-2020 | |
| Corcept Therapeutics | $37.84 | 2022-2023 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $33.69 | 2022 | |
| Antares Pharma, INC. | $33.26 | 2022-2024 | Xyosted |
| Phathom Pharmaceuticals, INC. | $32.08 | 2024-2025 | Voquezna |
| Genentech USA, INC. | $31.90 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $29.94 | 2022-2023 | Quviviq |
| Stryker Corporation | $29.56 | 2024 | Aequalis Perform |
| Astellas Pharma US INC | $28.87 | 2023 | Veozah |
| Ironshore Pharmaceuticals INC. | $28.82 | 2023 | Jornay Pm |
| Allergan, INC. | $22.99 | 2019 | |
| Halozyme INC | $22.76 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $21.83 | 2024 | Rexulti |
| Mylan Specialty L.P. | $20.13 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.73 | 2023 | Xifaxan |
| Lucid Diagnostics INC. | $14.09 | 2023 | |
| Corium, LLC | $13.76 | 2023 | Azstarys |
| Medtronic USA, INC. | $13.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.